Company / Net Income
CRISPR Therapeutics AG Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$581.6M
FY2025
5-year range
-$650.2M / $377.7M
FY2021-FY2025
Trend
-58.8%
vs FY2024
Sector context
#201 of 216
Health Care
What the data says
Among 216 Health Care companies, CRISPR Therapeutics AG is in the bottom 7% for net income. Net Income has fluctuated over the past 10 years, ranging from -$650M in FY2022 to $378M in FY2021.
Based on SEC 10-K filings.
-$582M in FY2025.
Declined from -$154M to -$582M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 216This company -$581.6M Sector average $454.3M
▼
-228.0% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 58.8% year-over-year.
- Ranks #201 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2021.
- Lowest net income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$581.6M | -58.8% |
| FY2024 | -$366.3M | -138.4% |
| FY2023 | -$153.6M | +76.4% |
| FY2022 | -$650.2M | -272.2% |
| FY2021 | $377.7M | +208.3% |
| FY2020 | -$348.9M | -621.8% |
| FY2019 | $66.9M | +388.5% |
| FY2018 | -$23.2M | +9.1% |
| FY2017 | -$25.5M | -263.9% |
| FY2016 | -$7.0M | +72.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026